International Business News - MNKD http://www.ibtimes.com All articles are copyrighted by IBTimes.com 400 100 http://www.ibtimes.com/ http://www.ibtimes.com/images/top_logo_ibt2_3.gif Among the earnings stories for Monday, Aug. 11, from AP Financial News: VALENCIA, Calif. (AP)--Biotechnology company MannKind Corp. reported a deeper second-quarter loss, as the company faced higher research and development costs. http://www.ibtimes.com/articles/20080811/earnings-roundup-mannkind-liberty-media.htm Mon, 11 Aug 2008 17:40:56 EDT Biotechnology company MannKind Corp. reported a deeper second-quarter loss, as the company faced higher research and development costs. MannKind reported a loss of $79.8 million, or 79 cents per share, for the second quarter. That compares with a loss of $72 million, or 98 cents per share, in the same quarter last year. http://www.ibtimes.com/articles/20080811/biotech-company-mannkind-corp-sees-wider-2q-loss.htm Mon, 11 Aug 2008 17:26:02 EDT Pharmaceutical giants Merck & Co., Bristol-Myers Squibb Co. and Novartis AG will be among the companies hoping to catch the attention of physicians at the American Diabetes Association's annual meeting this weekend. http://www.ibtimes.com/articles/20080605/diabetes-treatments-take-stage-at-ada-meeting.htm Thu, 05 Jun 2008 12:57:25 EDT Biotechnology company MannKind Corp. said Monday its first-quarter loss narrowed on lower research and development costs. The company lost $71.4 million, or 70 cents per share, compared with a loss of $73.1 million, or $1 per share, during the same period a year prior. Revenue rose to $20,000 from $10,000. During the most recent period, MannKind had about 28 million additional shares of common stock outstanding. http://www.ibtimes.com/articles/20080505/mannkinds-1q-loss-narrows-on-lower-costs.htm Mon, 05 May 2008 17:23:00 EDT MannKind shares traded heavily after the drug development company halted efforts to find a partner to market its Technosphere inhaled insulin. "Given current market sentiment, we have decided to sus... http://www.ibtimes.com/articles/20080410/mannkind-trades-heavily-on-insulin-scare.htm Thu, 10 Apr 2008 17:24:29 EDT Biotechnology company MannKind Corp. said Thursday that it is suspending partnership discussions for its inhalable insulin drug candidate following Pfizer Inc.'s warning of a potential lung cancer r... http://www.ibtimes.com/articles/20080410/mannkind-suspends-insulin-talks.htm Thu, 10 Apr 2008 09:56:29 EDT Shares of companies developing inhaled insulin products are plunging in Wednesday morning trading, after a Pfizer study linked Nektar Therapeutics' Exubera drug to lung cancer. Pfizer said six of t... http://www.ibtimes.com/articles/20080409/out-of-the-gate-inhaled-insulin-stocks.htm Wed, 09 Apr 2008 10:31:03 EDT The prospects for inhaled insulin suffered another damaging blow earlier this month after Eli Lilly & Co. ended its late-stage development program, citing a lack of confidence in the marketplace and possible regulatory hurdles. http://www.ibtimes.com/articles/20080320/market-spotlight-inhaled-insulin.htm Thu, 20 Mar 2008 17:45:46 EDT Among the stock activity stories for Monday, March 10, from AP Financial News: NEW YORK (AP) _ Shares of MannKind Corp. fell Monday over concerns the biotechnology company may join several peers in ending development of an inhaled insulin product. http://www.ibtimes.com/articles/20080310/movers-roundup-mannkind-pdl-biopharma.htm Mon, 10 Mar 2008 13:22:17 EDT Shares of MannKind Corp. fell Monday over concerns the biotechnology company may join several peers in ending development of an inhaled insulin product. http://www.ibtimes.com/articles/20080310/inhaled-insulin-worries-sink-mannkind.htm Mon, 10 Mar 2008 11:08:16 EDT Among the earnings stories for Tuesday, March 4, from AP Financial News: ANDOVER, Mass. (AP) _ NaviSite Inc., a provider of outsourced Web and e-commerce services, on Tuesday posted a smaller loss for its fiscal second quarter as new customers helped boost revenue and bookings. http://www.ibtimes.com/articles/20080304/earnings-roundup-navisite-staples.htm Tue, 04 Mar 2008 18:17:12 EST MannKind Corp., which is conducting advanced tests for a diabetes treatment, said Tuesday its fourth-quarter loss increased as expenses rose. But results beat analyst expectations, and shares rose 30 cents, or 4.6 percent, to $6.87 in afternoon trading. http://www.ibtimes.com/articles/20080304/mannkinds-4q-loss-widens-on-expenses.htm Tue, 04 Mar 2008 14:35:24 EST